# VectorY Therapeutics funding rounds and investors

As of 14 Nov 2026, VectorY Therapeutics has raised $82.9M across 1 verified round on record (amounts in other currencies converted to USD), plus 2 rounds still being checked; latest: €74.5 million ($83.5 million) Series A, announced 11 Nov 2026.

A clinical-stage biotechnology company pioneering vectorized antibody therapies for neurodegenerative diseases

Website: https://www.vectorytx.com  
Headquarters: Amsterdam  
Page: https://fireround.dev/companies/vectory

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2026-11-11 | Series A | €74.5 million ($83.5 million) | not stated | ALS Investment Fund, Angelini Ventures, BGV, BioGeneration Ventures, EIB, Eli Lilly, EQT Life Sciences, European Investment Bank (EIB), Forbion, Forbion, through its Growth and Ventures strategies, Insight Partners, Invest-NL, MRL Ventures Fund | [businesswire.com](https://www.businesswire.com/news/home/20261111459710/en/VectorY-Therapeutics-Raises-%E2%82%AC74.5-Million-%2483.5-Million-to-Advance-Clinical-and-Preclinical-Neurodegenerative-Disease-Pipeline), [eu-startups.com](https://www.eu-startups.com/2026/11/amsterdams-vectory-therapeutics-raises-e74-5-million-to-tackle-als-and-other-neurodegenerative-diseases), [allsci.com](https://allsci.com/news/biotech/vectory-therapeutics-raises-eur-745m-advance-als) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.